In which areas is artificial intelligence most mature? What are the challenges to widespread adoption? Tufts and DIA recently teamed up to explore these questions.
New this year to the discussion at DIA is the conversation around data ownership, as the industry continues to face a deluge of information from more sources than ever.
As regulators work to advance the modern clinical trial, the risk-averse clinical research industry is falling behind in the race to bring new therapies to patients, says an industry expert, echoing the former FDA commissioner’s calls for innovation.
University of Rochester Medical Center joined the global health research network aiming to ‘expand its access to advanced clinical trials’, TriNetX announced.
CRF Bracket is expanding its offering across the Asia-Pacific region with a new Tokyo office to help it better serve the area’s diverse and underserved patient population.
Biomarkers have the potential to improve drug development productivity by 34% over the next five years, during which period pre-screened patient pools and the application of predictive analytics also will help address the increasing complexity of clinical...
Acorn AI is designed to answer questions across all phases of drug development, making data “liquid” to help pharma make quick “go/no-go” decisions, accelerate clinical trials, and demonstrate value.
China-based pharmaceutical companies betting big and small biopharma able to quickly innovate will drive the use of AI for drug discovery – a market some analysts predict will reach a valuation of $20bn by 2024.
Drug development – a dynamic and evolving process – is modernizing at an unprecedented rate, says industry expert, who stresses that change must continue to fully explore the opportunities.
Live updates from Bridging Clinical Research and Clinical Health Care this past week in Washington, D.C. touching on the challenges of clinical trials to the reinvention of research solutions.
The MI-based CRO MMS Holdings is among the team at the Health Analytics Collective, a research group hoping to reduce the need for new clinical trials by using readily available data – and an MIT-incubated programming language.
The All of Us research program is expanding its data collection abilities via Fitbit – a move that further demonstrates the industry’s increasing adoption of a BYOD approach, says Thread executive.
